

REMARKS

Favorable reconsideration and allowance of the subject application are respectfully requested.

New claims 66 and 67 are based upon the subject matter deleted from claim 65.

The art cited in the subject Official Action has been carefully considered by the Applicants together with the Examiner's comments relative thereto.

Claims 41 and 58-65 stand rejected under 35 U.S.C. §103 as being unpatentable over von Borstel et al in view of Chu et al. Reconsideration is requested.

The von Borstel et al reference discloses acylated derivatives of uridine and cytidine. Chu et al teaches the use of uridine phosphorylase inhibitors in order to potentiate the chemotherapeutic effect of pyrimidine nucleoside analogs such as 5-fluorouridine by preventing the degradation of the nucleoside analog (not by elevating uridine levels).

Claim 65 stands rejected under 35 U.S.C. §112, second paragraph. Reconsideration is requested.

This claim has been amended thus obviating this rejection.

Applicants respectfully submit that none of the cited art of record, either taken alone or in combination, discloses, suggests or renders obvious the invention as claimed herein.

von Borstel, et al
Serial No. : 08/463,740


In view of the above, Applicants respectfully submit that all claims now pending herein fully and patentably define the present invention over the applied art of record. As such, early receipt of the Official Notice of Allowance is awaited.

Should any small matters remain outstanding, the Examiner is encouraged to telephone Applicants' undersigned attorney so that same can be resolved without the necessity of an additional Action and response thereto.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



Thomas E. Byrne
Reg. No. 32,205

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
TEB/lfo